Kodiak Sciences (KOD) Cash from Investing Activities (2017 - 2026)
Kodiak Sciences (KOD) posted Cash from Investing Activities of -$942000.0 for Q1 2026, down 2090.7% on a QoQ basis from -$43000.0 in Q4 2025, and down 248.89% year-over-year from $632686.6 in Q1 2025.
Kodiak Sciences (KOD) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Kodiak Sciences' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$942000.0 for Q1 2026.
- Quarterly Cash from Investing Activities fell 248.89% year-over-year to -$942000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 million (down 37.14% YoY) and the FY2025 annual result came in at -$506000.0, up 32.98% from the prior year.
- Cash from Investing Activities was -$942000.0 for Q1 2026 at Kodiak Sciences, down from -$43000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $173.4 million in Q1 2023 and bottomed at -$444.0 million in Q2 2022.
- A 5-year average of -$5.3 million and a median of -$166000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 8042.92% — and 2023, when it soared 1048.14%.
- Kodiak Sciences' Cash from Investing Activities stood at $67.0 million in 2022, then tumbled by 141.49% to -$27.8 million in 2023, then surged by 99.55% to -$124000.0 in 2024, then surged by 65.32% to -$43000.0 in 2025, then tumbled by 2090.7% to -$942000.0 in 2026.
- Business Quant data shows KOD's Cash from Investing Activities at -$942000.0 in Q1 2026, -$43000.0 in Q4 2025, and -$60000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Kodiak Sciences | 2.62 Bn | 2.62 Bn | - | -942,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -942,000.00 |
| Mar 31, 2026 | -942,000.00 |
| Dec 31, 2025 | -43,000.00 |
| Dec 31, 2025 | -43,000.00 |
| Sep 30, 2025 | -60,000.00 |
| Sep 30, 2025 | -60,000.00 |
| Jun 30, 2025 | -133,000.00 |
| Jun 30, 2025 | -133,000.00 |
| Mar 31, 2025 | -270,000.00 |
| Mar 31, 2025 | -270,000.00 |
| Dec 31, 2024 | -124,000.00 |
| Dec 31, 2024 | -124,000.00 |
| Sep 30, 2024 | -205,000.00 |
| Sep 30, 2024 | -205,000.00 |
| Jun 30, 2024 | -260,000.00 |
| Jun 30, 2024 | -260,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Dec 31, 2023 | -27.80 Mn |
| Dec 31, 2023 | -27.80 Mn |